Maven Securities’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-23,000
Closed -$558K 745
2025
Q2
$558K Buy
+23,000
New +$536K 0.01% 577
2025
Q1
Sell
-77,000
Closed -$2.04M 946
2024
Q4
$2.04M Buy
+77,000
New +$2.09M 0.05% 281
2024
Q1
Sell
-30,600
Closed -$881K 819
2023
Q4
$881K Sell
30,600
-11,300
-27% -$342K 0.02% 512
2023
Q3
$1.39M Buy
41,900
+400
+1% +$14.1K 0.02% 513
2023
Q2
$1.52M Buy
41,500
+6,200
+18% +$241K 0.02% 347
2023
Q1
$1.44M Sell
35,300
-6,500
-16% -$281K 0.03% 371
2022
Q4
$2.12M Sell
41,800
-20,400
-33% -$978K 0.05% 233
2022
Q3
$2.72M Buy
62,200
+43,200
+227% +$2.1M 0.05% 234
2022
Q2
$996K Buy
19,000
+6,400
+51% +$326K 0.03% 363
2022
Q1
$652K Buy
12,600
+5,400
+75% +$280K 0.02% 461
2021
Q4
$425K Sell
7,200
-75,700
-91% -$3.75M 0.01% 599
2021
Q3
$3.57M Sell
82,900
-103,900
-56% -$4.6M 0.12% 127
2021
Q2
$7.32M Buy
186,800
+163,500
+702% +$6.36M 0.29% 58
2021
Q1
$844K Buy
+23,300
New +$827K 0.04% 475
2020
Q4
Sell
-20,237
Closed -$702K 787
2020
Q3
$702K Sell
20,237
-18,023
-47% -$632K 0.06% 319
2020
Q2
$1.18M Sell
38,260
-7,589
-17% -$258K 0.08% 193
2020
Q1
$1.42M Buy
45,849
+4,216
+10% +$144K 0.17% 90
2019
Q4
$1.55M Buy
+41,633
New +$1.48M 0.14% 125

Other funds holding PFE

Maven Securities's PFE Position: Q2 2026 in Review

Maven Securities sold out of Pfizer (PFE) in Q2 2026, closing a stake of 26,366 shares — an estimated $739K sold.

Maven Securities first reported a position in PFE in Q1 2020 and held it in 15 quarters. The position peaked at $1.5M in Q3 2022. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Maven Securities reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • Maven Securities sold 26,366 Pfizer shares in Q2 2026, an estimated $739K.
  • Maven Securities first reported a position in Pfizer in Q1 2020 and held it in 15 quarters.
  • Maven Securities's Pfizer position peaked at $1.5M in Q3 2022.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.